Neximmune

Neximmune EBIT per Share

The EBIT per Share of Neximmune (NEXI) as of Oct 18, 2026 is -65.71 USD. In the previous year, EBIT per Share was -65.74 USD — a change of -0.05% (higher).

EBIT per Share

-65.71USD

YoY

-0.05%

Last updated:

EBIT per Share of Neximmune is 2022 -65.71 USD. EBIT per Share of Neximmune was 2021 -65.74 USD. It decreases by -0.05% higher compared to the previous year.

The Neximmune EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-15.40 USD
Jan 1, 2019
-24.29 USD
Jan 1, 2020
-32.38 USD
Jan 1, 2021
-65.74 USD
Jan 1, 2022
-65.71 USD
Jan 1, 2023 (e)
-35.50 USD
Jan 1, 2024 (e)
-30.39 USD
Jan 1, 2025 (e)
-24.43 USD
The Neximmune EBIT per Share history
YEAREBIT per ShareYoY
est-24.43USD-19.62%
est-30.39USD-14.39%
est-35.50USD-45.97%
-65.71USD-0.05%
-65.74USD+103.01%
-32.38USD+33.32%
-24.29USD+57.78%
-15.40USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neximmune Stock analysis

What does Neximmune do? Neximmune Inc, trading under ticker NEXI, is a US-based biotechnology company headquartered in Gaithersburg. Founded in 2021, the company went public on February 12, 2021. It employs 50 people and operates in the Health Care sector. Neximmune focuses on developing immunotherapies using its Artificial Immune Modulation (AIM) platform, which employs nanoparticles to direct T cell responses. The company's product candidates include NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. Its AIM technology constructs synthetic dendritic cells to generate targeted immune responses. The company is clinical-stage, developing treatments for oncology and autoimmune disorders. Neximmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neximmune stock

EBIT per Share of Neximmune is -65.71 USD in 2022.

EBIT per Share of Neximmune changed from -65.74 USD to -65.71 USD, representing a -0.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Neximmune since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Neximmune

All Key Metrics — Neximmune